Mapol Inc. is pleased to announce that Peripharm will be collaborating with Mapol in the development of Budget Impact Analyses and Health Economic Analyses as part of Mapol’s complete end-to-end private payer and public payer Market Access submission services in Canada.

Jean Lachaine, President of PeriPharm Inc., and his dynamic team have over 14 years of experience specializing in pharmacoeconomics with proven expertise in economic evaluation, model development and adaptation, drugs and medical services databases analysis, and real world evidence studies. PeriPharm has extensive experience working with Canadian and Global pharmaceutical and biopharmaceutical companies.

Welcome to our team, Jean!